The experts hope that these recommendations will improve the management of cutaneous side effects and hence quality of life for oncology patients. Keywords:skin care, cosmetic, dermatological toxicity, folliculitis, xerosis, chemotherapy, radiotherapy, supportive care, cancer, consensus == Introduction == Systemic cancer therapy, and radiotherapy, or a combination thereof, has improved the management of many malignancies as well as individual survival rates. side effects and hence quality of life for oncology patients. Keywords:skin care, cosmetic, dermatological toxicity, folliculitis, xerosis, chemotherapy, radiotherapy, supportive care, malignancy, consensus == Introduction == Systemic malignancy therapy, and radiotherapy, or a combination thereof, has improved the management of many malignancies as well as patient survival rates. Morusin However, they are also associated with uncomfortable and disfiguring cutaneous reactions, which continue to be an important issue for both patients and treating physicians.1,2Therefore, preventing and managing these reactions is becoming increasingly important.3 Adverse cutaneous reactions associated with radiotherapy or chemotherapeutic agents are comprehensively explained in the literature. Hair and nails may be affected, causing alopecia, paronychia, and other abnormalities. Skin barrier function may also be disturbed, resulting in folliculitis (skin rash), xerosis, pruritus, hyperpigmentation, and hand and foot erythema. Additionally, the skin becomes more sensitive to allergens and prone to contamination, and becomes more sensitive to ultraviolet radiation.2,48The exact mechanisms involved in the pathophysiology are only partly understood.4 Radiotherapy causes a variety of side effects, commonly referred to as radiodermatitis. One of the most common acute skin reactions, radiodermatitis can range from moderate erythema to severe confluent moist desquamation. All patients receiving radiotherapy are at risk of developing these reactions. Therefore, early assessment and management promotes patient comfort and ease and enhances quality of life. 911 Combining radiotherapy and systemic therapy may exacerbate cutaneous reactions, resulting in severe xerosis, inflammation, skin thinning, and necrosis of the upper dermis and epidermis.12Side effects tend to appear early on, and although mostly moderate at onset, can become severe and significantly impair quality of life. 6These reactions may lead to dose reduction or discontinuation of therapy, which could be detrimental to the outcome of treatment.13Given that disturbances of barrier function are common to all treatments, close and prompt collaboration between oncologists and dermatologists would ensure the best decisions are made for patients, with the objective of managing adverse cutaneous reactions from the Morusin start of treatment to minimize therapy changes.1417 Several publications provide recommendations or algorithms for pharmaceutical treatment, FLJ39827 but skin care itself remains unclear.3,10,12,18,19Therefore, the authors intend to provide further support for the choice of nonpharmaceutical skin care and cosmetic products for all those cancer treatment regimens. This paper is intended to provide oncology health care professionals with Morusin recommendations for the most adequate use of nonpharmaceutical skin care products to more effectively prevent and Morusin manage skin toxicity and to improve quality of life for cancer patients. == Literature review == These recommendations are based on an extensive literature review of skin toxicity and use of makeup products and nonpharmaceutical skin care products adjunctive to current malignancy treatments. The authors have focused on skin, mucosal, and nail disorders following oncology treatments as well as on conclusions reached during an expert getting together with of six impartial European dermatologists and one oncologist held in November 2011. An extensive literature review using BIOSIS and PubMed was performed. Search terms selected had been: emollient + tumor + epidermis + standard of living, sunscreen + tumor + epidermis, hygiene + cancers, make-up + tumor, radiotherapy + epidermis toxicity, regular chemotherapy + epidermis toxicity, and targeted therapy + epidermis toxicity. Through the conference, the literature regarding different epidermis toxicities linked to targeted chemotherapy and radiotherapy aswell as standard of living during oncology therapy was evaluated. Unfortunately, to time, evidence-based support for the adjunctive usage of skin care items in oncology therapy continues to be scarce. Practice is dependant on anecdotal reviews or research with small handles mainly. As a result, the professional group discussed suitable dermocosmetic skincare products for a particular amount of cutaneous reactions, and finished their suggestions with current practice and personal Morusin knowledge. == Explanations == Dermocosmetic skincare was defined with the professional -panel as personal cleanliness, cleansing, moisturizing, and photoprotection using beauty or nonpharmaceutical items. These products must have been examined clinically in sufferers with epidermis diseases and confirmed an excellent tolerance profile. Systemic therapy, for the reasons of the paper, identifies key cytotoxic agencies such as for example alkylating agencies, antimetabolites, anthracyclines, and topoisomerase inhibitors. Systemic therapy also contains targeted (biologic) therapy or immunotherapy.18,20,21Radiotherapy refers.